TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05202288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Administration of r-VSV-ZEBOV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Administration of r-VSV-ZEBOV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Administration of r-VSV-ZEBOV vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ervebo
Description: Administration of r-VSV-ZEBOV vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ervebo
Description: Administration of r-VSV-ZEBOV vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inmazeb
Description: Administration of Inmazeb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inmazeb
Description: Administration of Inmazeb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inmazeb
Description: Administration of Inmazeb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inmazeb
Description: Administration of Inmazeb
Study: NCT05521022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-02
Description: AT-02 via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-02
Description: AT-02 via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-02
Description: AT-02 via IV infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AT-02 (Placebo)
Description: Normal saline solution via IV infusion
Study: NCT06716879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donzakimig
Description: Drug: Donzakimig Pharmaceutical form: Subcutaneous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Pharmaceutical form: Subcutaneous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Pharmaceutical form: Subcutaneous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Pharmaceutical form: Subcutaneous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Pharmaceutical form: Subcutaneous solution
Study: NCT06745336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-001
Description: CS-001 Topical Treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Topical Solution
Description: Placebo Topical Solution
Study: NCT05982600

Intervention type: DIAGNOSTIC_TEST
Intervention: 3 people Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by 3 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.

Intervention type: DIAGNOSTIC_TEST
Intervention: 5 people Teledermatological triage (TDT)
Description: The skin lesion is assessed, diagnosed and triaged by 5 dermatologist assessors. Worst case and majority consensus assessments are calculated separately.
Study: NCT06047262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapansutrile
Description: Patients receive investigational product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients receive placebo.
Study: NCT06290544

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care plus additional examinations
Description: The patient will undergo good clinical practice examinations according to guidelines plus The patient will undergo to the evaluation of endothelial dysfunction with ENDOPAT 2000 and whole blood sampling for future omics studies
Study: NCT05403307

Intervention type: BIOLOGICAL
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: BIOLOGICAL
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: BIOLOGICAL
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: BIOLOGICAL
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: BIOLOGICAL
Intervention: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine
Description: Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine

Intervention type: BIOLOGICAL
Intervention: CoronaVac COVID-19 vaccine
Description: CoronaVac COVID-19 vaccine
Study: NCT00012987

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quality Improvement
Study: NCT05397457

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-level light therapy
Description: Device: Hair Boom 69~All participants within the experimental group will undergo low-level light therapy sessions 3 times a week for the total duration of 4 weeks starting at their last CT administration.~If the participants can not cooperate to receive the therapy 3 times a week due to personal reasons, we will recommend that they undergo 2 courses of the therapy per week at least and finish the 12 courses of the intervention in 6 weeks.
Study: NCT05082883

Intervention type: DIAGNOSTIC_TEST
Intervention: Risk Assessment Cognitive Screening
Description: Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks

Intervention type: DIAGNOSTIC_TEST
Intervention: Risk Assessment Cognitive Screening
Description: Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks

Intervention type: DIAGNOSTIC_TEST
Intervention: Risk Assessment Cognitive Screening
Description: Completion of a risk assessment cognitive screening app that includes working memory and voice-based tasks
Study: NCT06062706

Intervention type: PROCEDURE
Intervention: Donor hepatectomy
Description: Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach.

Intervention type: PROCEDURE
Intervention: Donor hepatectomy
Description: Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach.

Intervention type: PROCEDURE
Intervention: Donor hepatectomy
Description: Donor hepatectomy is a surgical procedure to resect a portion of the liver from a living donor for transplantation. This usually involved the right lobe, the left lobe or the left lateral section of the liver. Depending on the surgical method, this can be achieved through open, laparoscopic, or robotic-assisted techniques.~As for the recipient, liver transplantation involves a total hepatectomy of the diseased liver from the recipient and implantation of the liver graft from the donor. This is typically performed using the open surgical approach.
Study: NCT04675255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frequently sampled glucose tolerance testing
Description: Frequently sampled glucose tolerance testing
Study: NCT04913519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDM-105795
Description: TDM-105795 topical solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for TDM-105795 topical solution
Study: NCT05992987

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine deaminase serum level
Description: Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Adenosine deaminase serum level
Description: Adenosine deaminase will be measured by enzymatic (clorometric / kinetic) method (Diazyme laboratories, San Diego, California, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: IgE antibodies serum level
Description: Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: IgE antibodies serum level
Description: Level of IgE will be measured by electrochemiluminesence immunoassay (ECLIA, automatic cobase immunoassay, Roche Diagnostics GmbH, Mannheim, USA).
Study: NCT05158010

Intervention type: OTHER
Group type: OTHER
Intervention: HELIX's follow-up
Description: * Visit 1 (Day 0): clinical examination (anthropometry, bioimpedance, blood pressure,spirometry), neurodevelopment computer testing, questionnaires (Physical activity,diet, psychological distress, tobacco exposure, pubertal development, sleeping patterns, light exposure before going to sleep, outdoor environment (green spaces, noise), address history, home environment, socio-economic status, noise, psychological distress, medical history, medication use) 7 consecutive days (minimum) of personal exposure monitoring including wearing an actigraph, a Smartphone (GPS data), carrying a NO2 diffusion tube, collection of hair, stool, urines (2 urines during 6 consecutive days) and filling a sleep and physical activity diary~* Visit 2 (Day 8): blood collection early in the morning and collection of all the 7- days personal monitoring material, and stools and urines samples.
Study: NCT04675255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Frequently sampled glucose tolerance testing
Description: Frequently sampled glucose tolerance testing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal subcutaneous adipose tissue biopsy
Description: abdominal subcutaneous adipose tissue biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: abdominal subcutaneous adipose tissue biopsy
Description: abdominal subcutaneous adipose tissue biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan to assess intrahepatic triglyceride content
Description: MRI scan to assess intrahepatic triglyceride content

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI scan to assess intrahepatic triglyceride content
Description: MRI scan to assess intrahepatic triglyceride content
Study: NCT04238234

Intervention type: DEVICE
Intervention: IVC Ultrasonography
Description: Ultrasound measurements will be performed using a curved transducer set to abdominal mode (1-5 MHz; Acuson x300; Siemens Healthcare, Seoul, Korea). IVC variation will be assessed using ultrasound in the long-axis (sagittal) view. IVC diameter will be measured 1 cm distal to its junction with hepatic vein either by 2-D or M modes via a subcostal approach according to the methodology described by the American Society of Echocardiography . A two-dimensional image of the IVC as it enters the right atrium will be first obtained.

Intervention type: DEVICE
Intervention: Plethysmographic variability index (PVI) and perfusion index readings (PI)
Description: The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA).~PVI (%) is a measure of the dynamic change in PI that occurs during one or more complete respiratory cycles, calculated as:~PVI= \[(PImax-PImin)/PImax\] x100
Study: NCT06747585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALE.P02
Description: ALE.P02, will be administered by IV infusion according to the assigned arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALE.P02
Description: ALE.P02, will be administered by IV infusion according to the assigned arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALE.P02
Description: ALE.P02, will be administered by IV infusion according to the assigned arms.
Study: NCT06746480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Description: Intratumoral injection only. The dosing date is Days 1 through 3.
Study: NCT06746987

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation
Description: After the appropriate sample group for the research is created, study and control groups will be determined. Firstly, randomization of the study and control groups in the research will be done by an independent researcher on the randomizer.org website. Secondly, the Pitsburg Sleep Quality Scale and PERMA test will be applied to the study and control groups as a pre- test. Thirdly, theta healing meditation will be applied to the study group for 4 weeks, 2 days a week, 15- 30 minutes a day. After the 4 week meditation practice is completed with the study group, a final test will be given to the study and control groupsthe Pitsburg Sleep Quality Scale and PERMA test will be applied as the final test.
Study: NCT06746272

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane Block
Description: Ultrasound guided Serratus anterior block will be performed according to the analgetic standard in our department using an ultrasound guided transducer to inject 2mg/kg of 0.5% ropivacaine with an adjuvant. A sterile plaster will be placed on the puncture site after performing the block. Patients will receive i.v. analgesia according to the analgesic standard of care in our department.
Study: NCT06746909

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidomain cognitive training and physical training
Description: The cognitive training programme will be based on 8 cycles composed by 18 sessions of exercises and activities aimed at stimulating multiple cognitive functions. Each cycle will last 3 weeks, after which the same kind of cognitive stimulation sessions will be restarted, with exercises and activities of increased complexity. Each cycle will be structured in sessions aimed at stimulating specific cognitive domains and in sessions focused on multimodal activities (music-therapy, cineforum, etc.).~The physical training will include aerobic exercise on an ergometer cycle, whose duration will be increased gradually from 10 to 20 minutes followed by exercises targeted to improve muscle strength, physical function, neuromuscular control and flexibility.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multidomain cognitive training and physical training
Description: The cognitive training programme will be based on 8 cycles composed by 18 sessions of exercises and activities aimed at stimulating multiple cognitive functions. Each cycle will last 3 weeks, after which the same kind of cognitive stimulation sessions will be restarted, with exercises and activities of increased complexity. Each cycle will be structured in sessions aimed at stimulating specific cognitive domains and in sessions focused on multimodal activities (music-therapy, cineforum, etc.).~The physical training will include aerobic exercise on an ergometer cycle, whose duration will be increased gradually from 10 to 20 minutes followed by exercises targeted to improve muscle strength, physical function, neuromuscular control and flexibility.
Study: NCT06746350

Intervention type: DEVICE
Group type: OTHER
Intervention: Thermotherapy
Description: Radio frequency-induced heat treatment using the ThermoMed device at 50-degree centigrade for 30 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermotherapy
Description: Radio frequency-induced heat treatment using the ThermoMed device at 50-degree centigrade for 30 seconds.
Study: NCT06747975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone and Ondansetron
Description: patients will receive Caudal epidural block (0.5 mL/kg of bupivacaine 0.25% plus dexa- methasone 0.1 mg/kg plus 4mg ondansetron ), and IV 5 mL normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + saline
Description: patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine + saline
Description: patients will receive caudal epidural block (0.5 mL/kg of bupivacaine 0.25% only) and IV 5 mL normal saline
Study: NCT06747156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABO2203 Injection
Description: Name of Active Ingredient: mRNA encoding CD19/CD3 T cell engager
Study: NCT06747325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fei Re Qing Granules
Description: Fei Re Qing Granules (Ingredients: Scutellaria baicalensis \[Huang Qin\], Trichosanthes kirilowii \[Gua Lou\], Forsythia suspensa \[Lian Qiao\], Fritillaria thunbergii \[Zhe Bei Mu\], etc.)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine standard treatments
Description: Routine standard treatments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine standard treatments
Description: Routine standard treatments
Study: NCT05159141

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral sleep intervention
Description: The intervention consists of an infant behavioral sleep protocol. In the tailored intervention approach, parents are asked to implement the behavioral protocol at bedtime and at subsequent night wakings.
Study: NCT06172088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Sieben days of online supervised prolonged therapeutic fasting (max. 350 kcal/d).
Study: NCT06747325

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo granules
Description: The placebo granules are prepared using 5% of the active drug, ensuring consistency in appearance, weight, color, and odor with the Fei Re Qing Granules
Study: NCT05100472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: ADT will include bicalutamide 50 mg PO daily started 1-2 weeks before leuprolide 22.5mg IM or SQ delivered every 3 months x 2. Bicalutamide will be continued through radiation and then discontinued on the day of the last fraction. Leuprolide can be given at different doses, but must be given for a total planned duration of 6 months.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: After approximately 3 months (+/- 1 month) of neoadjuvant ADT, patients will undergo general anesthesia for outpatient transperineal high dose rate (HDR) interstitial prostate brachytherapy implant.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated pelvic External beam radiation
Description: Patients will receive image-guided, intensity-modulated, hypofractionated radiation therapy targeting the prostate, seminal vesicles and pelvic lymph nodes to a dose of 25 Gy in 5 fractions delivered daily.
Study: NCT06326866

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Study: NCT06747416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN057
Description: KN057 will be administered subcutaneously once a week.
Study: NCT06326866

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: Otoacoustic emissions (non-invasive)
Description: There is no invasive intervention in the study. Individuals with predetermined blood types will be included in the study.
Study: NCT05471726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prospective audit-and-feedback
Description: The stewardship team will review patients who are on antibiotics, have an uncomplicated infection, and are eligible to continue antibiotics after discharge. Any recommendations from the stewardship team about optimizing antibiotic therapy will be presented to the primary prescriber in real-time with the goal of improving antibiotic selection and duration at hospital discharge.
Study: NCT06278064

Intervention type: OTHER
Intervention: Gastric Cancer
Description: Patients diagnosed with gastric cancer, including early stage gastric and advanced gastric cancer
Study: NCT05166902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (comfilcon A lens)
Description: 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (comfilcon A lens)
Description: 1 month

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (lehfilcon A lens)
Description: 1 month
Study: NCT06278064

Intervention type: OTHER
Intervention: Esophagus Cancer
Description: Patients diagnosed with esophagus cancer, including early esophagus gastric and advanced esophagus cancer
Study: NCT04854213

Intervention type: DEVICE
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Radiation treatment
Study: NCT04944316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Low-fat, plant-based diet
Study: NCT06747494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Description: Participants will receive a one-time general anesthesia dose during the total joint arthroplasty procedure as per standard of care.
Study: NCT04944316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Portion-controlled diet (compliant with ADA guidelines)
Study: NCT06747494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Description: Participants will receive a one-time spinal anesthesia dose during the total joint arthroplasty procedure as per standard of care.